Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30103245 | 1.00 | PIK3CD (0.50) | PIK3CDALOX12CYP1A2METAP2MDM2 | |
| SCHEMBL24090095 | 0.96 | PIK3CD (0.50) | PIK3CDALOX12CYP1A2METAP2MDM2 | |
| SCHEMBL29738614 | 0.96 | PIK3CD (0.46) | PIK3CDALOX12TDO2IDO2IDO1 | |
| SCHEMBL23958265 | 0.96 | PIK3CD (0.46) | PIK3CDALOX12TDO2IDO2IDO1 | |
| SCHEMBL24110807 | 0.94 | PIK3CD (0.45) | PIK3CDALOX12TDO2IDO2 | |
| SCHEMBL24110971 | 0.93 | POLB (0.46) | PIK3CDTDO2IDO2IDO1RAD52 | |
| SCHEMBL23958162 | 0.93 | PIK3CD (0.44) | PIK3CDALOX12CYP1A2METAP2TDO2 | |
| SCHEMBL24110982 | 0.91 | PIK3CD (0.43) | PIK3CD | |
| SCHEMBL24111023 | 0.90 | PSD (0.50) | PIK3CDALOX12ALDH1A1 | |
| SCHEMBL24110913 | 0.89 | POLB (0.50) | PIK3CDALOX12MDM2TDO2IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115427399-A | 2-heteroarylaminoquinazolinone derivatives | 住友制药株式会社 | 2022-12-02 | — | — | CN | disclosed |
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-16 | — | — | US | disclosed |
| WO-2021215537-A1 | 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | CRKL, CLIC4, CLIC1 | PIK3CD 3088/4885ALOX12 3240/4885CYP1A2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.